NCT07352969尚未招募2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter, 24 Months Treatment Duration, Dose Finding Study, to Evaluate Efficacy, Safety and Pharmacodynamics of IBI3016 in Mild to Moderate Hypertensive Patients
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 352
研究概览
简要总结
The purpose of this study is to evaluate the efficacy, safety and tolerability of IBI3016 or placebo, given subcutaneously, every 3 or 6 months, at different dose levels in patients with mild to moderate hypertension
详细描述
Phase 2, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and pharmacodynamics of IBI3016 in patients with mild to moderate hypertension. Multiple doses of IBI3016 will be tested against placebo, administered as subcutaneous injection.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent.
- •Males or females aged 18 to 75 years.
- •Diagnosis of primary hypertension without anti-HTN medication or with one anti-HTN medication
- •Mean sitting SBP ≥140 mmHg and < 170 mmHg measured by OBPM.
- •Participants able to understand and comply with study procedures.
排除标准
- •Known history of secondary hypertension.
- •Orthostatic hypotension.
- •Laboratory parameter assessments outside of range at screening：
- •Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 2× Upper Limit of Normal (ULN)
- •Total Bilirubin > 1.5× ULN
- •International Normalized Ratio (INR) > 2.0
- •Serum Potassium > 5 mg/L
- •Estimated Glomerular Filtration Rate (eGFR) ≤ 45 mL/min/1.73m²
- •QTcF > 480 ms
- •Medical condition, other than hypertension, requiring treatment with RAAS inhibitor.
- •Current or history of intolerance to ACEi and/or ARBs.
- •Acute myocardial infarction (AMI), unstable angina, percutaneous coronary intervention (PCI) , coronary artery bypass graft (CABG), ischemic or hemorrhagic stroke, transient ischemic attack, or clinically significant cardiac arrhythmias within 6 months prior to screening. Any history of congestive heart failure.
- •Other protocol-defined inclusion/exclusion criteria may apply
研究者
相似试验
尚未招募
1 期
A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT07336472Fortvita Biologics (USA)Inc.360
招募中
3 期
Study to assess the efficacy and safety of adjunctive NBI-1065845 in adults with Major Depressive Disorder (MDD)Major Depressive Disorder2024-519421-37-00Neurocrine Biosciences Inc.55
尚未招募
1 期
Phase Ib/II Study to Evaluate the Safety and Efficacy of IBI363 in Combination With Chemotherapy as Second-Line Therapy for Unresectable Locally Advanced or Metastatic Pancreatic CancerNCT07342725Ruijin Hospital48
招募中
2 期
A Phase 2b, multicenter, randomized, double-blind, placebo-controlled study to determine the efficacy and safety of BIIB122 in participants with Parkinson’s Disease (LUMA)Parkinson's Disease2023-505645-12-00Biogen Idec Research Limited311
招募中
2 期
Evaluation of NBI-1117570 in Inpatient Adults With SchizophreniaSchizophreniaNCT07288333Neurocrine Biosciences120